Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of CKD-397 in Healthy Male Subjects
NCT02645890Phase 1Completed
- Sponsor
- Chong Kun Dang Holdings
- Start
- Nov 2015
- Primary completion
- Dec 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of tadalafil + tamsulosin in benign prostatic hyperplasia (BPH) (2 arms), sponsored by Chong Kun Dang Holdings. Primary endpoint: Area Under the Curve from time 0 to last measurable concentration at 72 hours. Started Nov 2015; status: completed.
02
Drugs
tadalafil + tamsulosin
03
Conditions
benign prostatic hyperplasia (BPH)
Beyond the preview
Go deeper on NCT02645890.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02645890.